increased heart rate with glp 1 Effects of Glucagon-Like Peptide Receptor Agonist Initiation in Patients Failure With Reduced Ejection Fraction and Implantable Cardiac Devices TrimRX | Cardiovascular Risks of
Description
Conduct/data collection: Bronya Calvarysky, Yaara Gal, Shiri Kushnir, Adi Turjeman and Talia Diker Cohen
Single-cell messenger RNA sequencing reveals rare intestinal cell types
MS contributed to study design, collected and analyzed data, and wrote the manuscript
Int J Surg Oncol
Blue Shield of California is an independent member of the Blue Shield Association
Since then, several GLP-1s for obesity have been approved for new indications, such as secondary cardiovascular risk reduction (Wegovy), sleep apnea (Zepbound) and metabolic dysfunction-associated steatohepatitis, or MASH (Wegovy)
